Additionally, our results support that single anti-PD-L1 monotherapy presents a better AE profile compared to platinum-based chemotherapy in NSCLC patients, except for irAEs, but further studies are required to assess the potential benefit/risk ratio of monotherapy versus immunotherapy combination strategies. Here, CD274 is linked to non-small cell lung carcinoma.